Assessing the cost of parathyroidectomy as a treatment for uncontrolled secondary hyperparathyroidism in stage 5 chronic kidney disease

Conventional therapy for chronic kidney disease mineral bone disorder includes control of serum phosphate with phosphate binders and the supplementation of activated vitamin D. In many cases this proves inadequate, and in the UK parathyroidectomy (PTX) is recommended for patients who are otherwise surgical fit as it is perceived as less costly than calcimemetics. However, no details of the true cost of PTX have been published. AIMS: To describe the healthcare resource use and costs associated with patients receiving PTX as a treatment for uncontrolled secondary hyperparathyroidism in a single UK National Health Service (NHS) centre (Sheffield Kidney Institute).